Medicines for Malaria Venture

Medicines for Malaria Venture (MMV) is a not-for-profit public-private partnership that was established as a foundation in Switzerland in 1999. Its main mission is to reduce malaria in disease-endemic countries by developing and facilitating the delivery of antimalarial drugs.

History

edit

MMV was launched in 1999, with initial seed funding of US$4 million from the Government of Switzerland, the Department for International Development (UK), the Government of the Netherlands, the World Bank, and the Rockefeller Foundation.

Governance

edit

MMV is governed by a board of directors. The Chairman of MMV is Mr Alan Court.[1] MMV has a board of directors in North America, an Expert Scientific Advisory Committee which helps to identify projects, an Access & Product Management Advisory Committee and a Global Safety Board which reviews projects.[2]

Projects

edit

MMV's project portfolio states that their goals are:

  • Effective treatment against drug-resistant strains of Plasmodium falciparum
  • The potential for intermittent treatments (infants and pregnancy)
  • Safety for small children (less than 6 months old)
  • Safety in pregnancy
  • Effective treatment against Plasmodium vivax (including radical cure)
  • Effective treatment against severe malaria
  • and transmission-blocking treatment.

Open Source Malaria

edit

MMV started the Open Source Malaria project,[3] which encourages people to share procedures and results of open source research.[4] The Open Source Malaria, with researchers at the University of Sydney, supervised high school students at Sydney Grammar School who adapted a synthesis of Daraprim (pyrimethamine) using a less hazardous method.[5][6]

References

edit
  1. ^ "Board of Directors | Medicines for Malaria Venture". www.mmv.org. Archived from the original on 1 May 2024. Retrieved 12 December 2022.
  2. ^ "People & governance | Medicines for Malaria Venture". www.mmv.org. Archived from the original on 1 May 2024. Retrieved 12 December 2022.
  3. ^ "OpenSourceMalaria". OpenWetWare. 14 May 2017.
  4. ^ "OpenSourceMalaria:FAQ". OpenWetWare.
  5. ^ University of Sydney (30 November 2016). "Breaking good: School students make costly drug cheaply using open source approach". Eurekalert.
  6. ^ Knopf, Ehsan (1 December 2016). "Sydney high school students spend $27 to recreate drug that has retailed for $148k". 9news.com.au.
edit